Colon Cancer Clinical Trial

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Summary

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

View Full Description

Full Description

This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and TNO155 is a selective, orally bioavailable allosteric inhibitor of wild-type SHP2.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer)
Unresectable or metastatic disease
No available treatment with curative intent
Adequate organ function

Exclusion Criteria:

History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
Other active cancer
Cardiac abnormalities

Study is for people with:

Colon Cancer

Phase:

Phase 1

Estimated Enrollment:

86

Study ID:

NCT04330664

Recruitment Status:

Active, not recruiting

Sponsor:

Mirati Therapeutics Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 12 Locations for this study

See Locations Near You

UCLA Jonsson Comprehensive Cancer Center
Los Angeles California, 90095, United States
UC Irvine Health
Orange California, 92868, United States
Northwestern
Chicago Illinois, 60611, United States
Cancer Center of Kansas
Wichita Kansas, 67214, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Dana Farber
Boston Massachusetts, 02215, United States
Henry Ford
Detroit Michigan, 48202, United States
Washington University School of Medicine Siteman Cancer Center
Saint Louis Missouri, 63110, United States
NYU Perlmutter Cancer Center
New York New York, 10016, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10021, United States
NEXT Oncology
San Antonio Texas, 78229, United States
Froedtert Hospital & Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States

How clear is this clinincal trial information?

Study is for people with:

Colon Cancer

Phase:

Phase 1

Estimated Enrollment:

86

Study ID:

NCT04330664

Recruitment Status:

Active, not recruiting

Sponsor:


Mirati Therapeutics Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.